This page is available in multiple languages
Select Language

IPO Valbiotis

Back

Listing of Valbiotis on Euronext

Sébastien Peltier, CEO of Valbiotis, opens the trading day in Paris.

Valbiotis is a biopharmaceutical company specializing in the research and development of preventive and therapeutic products based on polymolecular complexes indicated at specific stages of progression of chronic metabolic pathologies such as type 2 diabetes, obesity, dyslipidemia or NASH (Non-Alcoholic Steatosis Hepatic).